K9 Immunity Plus Soft Chews: Product Profile

K9 Immunity Plus is a named branded product for Dogs; manufacturer positioning must be kept separate from independent clinical evidence.

Soft chew; current official page states 4,000 mg active ingredients per chew. Intended species: Dogs.

Cordyceps; Agaricus blazei; Reishi; Turkey Tail; Maitake; Shiitake; colostrum; fish oil; brewer’s yeast; vitamin E. The mushroom portion is presented as the Immune Assist complex.

The manufacturer positions the Plus chew as more intensive multi-level immune and recovery support for dogs facing cancer, surgery, age-related decline, or chronic weakness. This positioning differs materially from the capsule product because the chew also contains colostrum, fish oil, brewer’s yeast, and vitamin E.

May be discussed only as adjunctive/supportive care within a veterinarian-led plan; it must not replace diagnosis, staging, standard treatment, symptom control, or emergency care.

Define a modest supportive goal, objective review date, adverse-effect plan, and stopping rule with the veterinarian.

Bring the current label, lot, complete ingredient panel, seller and country version, and every medicine and supplement to the treating veterinarian.

The official page provides ingredient explanations but no controlled canine oncology trial of the finished K9 Immunity Plus chew was identified. Evidence about a single mushroom extract, beta-glucans generally, fish oil, or another product cannot establish efficacy or safety of this combination. There is no verified basis here for claiming tumor shrinkage, delayed recurrence, or longer survival.

Review mushroom, dairy/colostrum, fish, and yeast sensitivities; fat tolerance; pancreatitis history; immune-mediated disease; immunosuppressants; anticoagulants; vitamin E exposure; surgery; liver or kidney disease; and duplicate supplements. Soft-chew excipients and market-specific labels should be checked on the physical package. Stop and contact the veterinarian after an unexpected reaction.

No universal compatibility conclusion is made. Review the complete label and individualized treatment plan with the veterinarian.

Marketed as a canine supplement through a multilingual European channel. The manufacturer describes local certification, but a current public competent-authority record for this exact chew was not independently located. It must not be described as an approved anticancer veterinary medicine.

European Union; Multiple European-language markets

Record the exact chew version, market, lot, ingredient panel, start date, and intended supportive outcome. Follow appetite, vomiting, diarrhea, stool quality, itching, facial swelling, activity, weight, and medication adherence. Objective tumor assessments and treatment monitoring remain governed by the oncology plan, not by owner-perceived energy alone.